To treat or not to treat: Balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer

Journal of Supportive Oncology

Volumn 11, Issue 4, 2013, Pages 149-159

  Murphy, Barbara A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PLATINUM; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE; ZALUTUMUMAB;

ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; COMORBIDITY; DEHYDRATION; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FUNCTIONAL ASSESSMENT; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; MEDICAL DECISION MAKING; METABOLIC DISORDER; METASTASIS; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SEPSIS; SKIN MANIFESTATION; SKIN TOXICITY; SOCIAL SUPPORT; STOMATITIS; THROMBOCYTOPENIA; TUMOR BLEEDING; UROGENITAL TRACT DISEASE; VOMITING; WEIGHT REDUCTION; HEAD AND NECK TUMOR; PROGNOSIS; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SURVIVAL; TUMOR RECURRENCE;

HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84897571825     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.12788/j.suponc.0005     Document Type: Review

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. National Cancer Institute. SEER Stat Fact Sheets: Oral Cavity and Pharynx. Surveillance Epidemiology and End Results. http://seer.cancer. gov/statfacts/html/oralcav.html. Accessed July 24, 2012.
3. Pfister DG, Ang KK, Brizel D, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™:Head and Neck Cancers 2012; version 1.2012. http://www.nccn.org/ professionals/physician_gls/pdf/head-and-neck.pdf. Published: April 26, 2012. Accessed July 24, 2012.
4. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
5. Morton RP, Rugman F, Dorman EB, et al. Cisplatin and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15(3):283-289.
6. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat Rep. 1985;69(6):577-581.
7. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245-1251.
8. Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257-263.
9. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521-526.
10. Schrijvers D, Johnson J, Jiminez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group J Clin Oncol. 1998;16(3):1054-1059.
11. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562-3567.
12. Urba S, van Herpen CM, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: Final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 2012;10(19):4694-4705.
13. León X, Hitt R, Constenlaz M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005;17(6):418-424.
14. Vermorken JB, Stohlmacher-Willimas J, Davidenko I, et al. Cisplatin and fluoruracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomized trial. Lancet Oncol. 2013;14(8):697-710.
15. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824-832.
16. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62(24):7350-7356.
17. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958-2970.
18. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980-1987.
19. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418-8424.
20. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77-78.
21. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol. 2009;27(suppl 15):6011. 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
22. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [correction appears in J Clin Oncol. 2009;27(20):3410]. J Clin Oncol 2009;27(11):1864-1871.
23. Fury MG, Sherman EJ, Lisa DM, et al. A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). J Clin Oncol. 2011;29(suppl May 20, 2011):5563. ASCO Meeting Abstracts, Part 1; abstract 5563.
24. Ciuleanu T, Nikolic V, Shmueli E, et al. Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol. 2011;29(suppl May 20, 2011):5563. ASCO Meeting Abstracts, Part 1; abstract 3580.
25. Roca JM, Alonso V, Paricay C, et al. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy. 2010;56(2):142-146.
26. Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer:a two-part pharmacokinetic/pharmacodynamic phase I doseescalation study. Ann Oncol. 2010;21(7):1537-1545.
27. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5577.
28. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578-5587.
29. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-2177.
30. Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21(10):1967-1973.
31. Machiels J-P, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an openlabel, randomised phase 3 trial. Lancet Oncol. 2011;12(4):333-343.
32. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1(1):41-48.
33. Seiwert TY, Fayette J, Delcampo JM, et al. A randomized, openlabel phase II study of afatinib (BIBW 2992) versus cetuximab in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients. Ann Oncol. 2010;21(suppl. 8):viii1-viii12. Proceedings of the 35th ESMO Congress; Milan, Italy, October 8-12, 2010; abstract 1010PD.
34. Lin YL, Lin IC, Liou JC. Symptom patterns of patients with head and neck cancer in a palliative care unit. J Palliat Med. 2011;14(5):556-559.
35. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
36. Rischin D, Young R, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28(27):4142-4148.
37. Yung KC, Piccirillo JF. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008;134(10):1045-1049.
38. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92(8):2109-2116.
39. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998;20(1):1-7.
40. Hathaway B, Johnson JT, Piccirillo JF, et al. Chemoradiation for metastatic SCCA: role of comorbidity. Laryngoscope. 2001;111(11 Pt 1):1893-1895.
41. Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol. 2009;27(12):1983-1991.
42. Rose BS, Jeong J-H, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. 2011;29(26):3503-3509.
43. de Graeff A, de Leeuw JRJ, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer. 2001;37(3):332-339.
44. Konski AA, Pajak TF, Movsas B, et al. Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol. 2006;24(25):4177-4183.
45. Terrell JE, Ronis DL, Fowler KE, et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130(4):401-408.
46. Pandey M, Devi N, Thomas BC, Kumar SV, Krishnan R, Ramdas K. Distress overlaps with anxiety and depression in patients with head and neck cancer. Psychooncology. 2007;16(6):582-586.
47. Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009;50(4):383-391.
48. Lazure KE, Lydiatt WM, Denman D, Burke WJ. Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck. 2009;31(7):888-892.
49. Howren MB, Christensen AJ, Karnell AH, Funk GF. Healthrelated quality of life in head and neck cancer survivors: impact of pretreatment depressive symptoms. Health Psychol. 2010;29(1):65-71.
50. Wells N, Murphy BA, Dietrich M, Forastiere A, Li Y, Cella D. Quality of life and pain assessment for head and neck cancer patients treated on E1395: a comparison of two different Cisplatinbased chemotherapy regimens. Proc Am Soc Clin Oncol 21: abstract 907, p227a, 2002.